OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$7.28
−4.59%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$7.60
From 52W high−77.70%
Volume547831.00
Market cap$450.77M
P/E (TTM)—
P/S (TTM)1520.6x
Div yield—
Key dataNov 4, 2026
Open
$7.60
From 52W high
−77.70%
Volume
547831.00
Market cap
$450.77M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.7x
P/E (TTM)
—
RSI (14)
29.6
MomentumView details →
1D Return
−4.59%
YTD Return
−65.35%
SummaryUpdated Jun 1, 2026
Oculis Holding AG (NASDAQ:OCS) is a clinical-stage biopharmaceutical company founded in Switzerland and publicly traded since May 2021. The company is headquartered in Zug, Switzerland, and focuses on developing innovative topical treatments for various eye diseases. As a clinical-stage biotechnology firm, Oculis has no approved products on the market yet and is currently advancing multiple drug candidates through different phases of clinical trials. The company represents a specialized approach to ophthalmology, targeting both front-of-the-eye conditions like dry eye disease and back-of-the-eye disorders such as diabetic macular edema.
Similar companies
Latest newsMore news →
Oculis Holding AG reported a quarterly loss of $0.37 per share, compared with a Zacks Investment Research, Inc. consensus estimate of a $0.49 loss and a $0.40 loss per share a year earlier.23h agoOculis Holding AG announced its financial results for the third quarter ended September 30, 2026.1d agoOculis Holding AG reported Phase 2 ACUITY biomarker data showing that privosegtor reduced post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein compared with placebo.14d ago